Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Recurrent Follicular Lymphoma · Refractory Follicular Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Contact: Study coordinator (Office Of Clinical Research) · OCRReferral@health.ucdavis.edu · 916-382-6970
Contact: Principal Investigator (Joseph M. Tuscano)

Study leads

Joseph M Tuscano
Principal Investigator
University of California, Davis

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Lymphoma

Abroad (travel likely)RecruitingPHASE3

Ghent, Belgium · Leuven, Belgium

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

B-Cell Non-Hodgkin Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Diffuse Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1

Jacksonville, United States

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Follicular Lymphoma · Relapsed and Refractory Follicular Lymphoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China · Guangzhou, China

Registry of Older Patients With Cancer

Chronic Myeloproliferative Disorders · Cognitive/Functional Effects · Leukemia

Abroad (travel likely)Recruiting

Boone, United States · Chapel Hill, United States